RLD2301

RLD2301 is an investigational drug developed by Hanmi Pharmaceutical. As of May 2025, it has reached Phase 1 clinical trials. The available data indicate that it is being studied for its safety and drug-drug interaction profile in healthy volunteers, specifically in combination with another investigational agent, RLD2007. The precise mechanism of action, molecular target(s), modality (e.g., small molecule or biologic), and therapeutic indication have not been disclosed publicly as of the latest updates. The only published clinical trial (NCT05862090) was a completed Phase 1 study evaluating oral administration in healthy adults[1][2][3][4].